Pharvaris (PHVS) Cash from Operations Growth (3y) (2023 - 2026)

Pharvaris (PHVS) Cash from Operations Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -5.07%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 33.08%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 16.64%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -7.60%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Pharvaris 2.17 Bn 1.88 Bn - -28.27%

Historic Data

Download Data
DateValue
Mar 31, 2026 -28.27%
Dec 31, 2025 -28.49%
Sep 30, 2025 -32.81%
Jun 30, 2025 -32.45%
Mar 31, 2025 -26.34%
Dec 31, 2024 -37.71%
Sep 30, 2024 -45.59%
Jun 30, 2024 -27.80%
Mar 31, 2024 -28.86%
Dec 31, 2023 -34.09%
Sep 30, 2023 18,493.89%
Jun 30, 2023 -23,051.02%
Mar 31, 2023 -119.25%